Ignite Creation Date:
2024-05-06 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06202885
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-12
First Post:
2023-12-18
Brief Title:
CAREMM-2306 Advanced Immunotherapy vs Classical Immunotherapy
Sponsor:
Seoul St Marys Hospital
Organization:
Seoul St Marys Hospital
Study Overview
Official Title:
A Comparative Study of Retrospective Outcomes Including Efficacy of Therapy Between Advanced Immunotherapy and Classical Immunochemotherapy in RelapsedRefractory Lymphoma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this retrospective study is to compare between the case cohort and control cohort
The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy bispecfic antibody andor antibody-drug conjugate
The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care
The main questions it aims to answer are
Survival times
Response outcomes
The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy bispecfic antibody andor antibody-drug conjugate
The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care
The main questions it aims to answer are
Survival times
Response outcomes
Detailed Description:
1 Primary endpoints Comparison of survival time by treatment between two groups
2 Secondary endpoints 21 Comparison of progression-free survival between two groups 22 Comparison of response rates between two groups 23 Comparison of input medical costs between two groups
2 Study subjects Patients treated for lymphoma at Yeouido St Marys Hospital and Seoul St Marys Hospital Both are located on Seoul Korea between May 2009 and June 2023
3 Selection criteria 31 Patients diagnosed with malignant lymphoma at Catholic Yeouido St Marys Hospital and Seoul St Marys Hospital between May 2009 and June 2023
32 Age 19 or older 33 Patients who treated with salvage chemotherapy for the relapsedrefractory lymphoma
4 Exclusion criteria 41 Patients suffering from acute leukemia 42 Patients additionally diagnosed with solid cancer colon cancer lung cancer stomach cancer etc during treatment
2 Secondary endpoints 21 Comparison of progression-free survival between two groups 22 Comparison of response rates between two groups 23 Comparison of input medical costs between two groups
2 Study subjects Patients treated for lymphoma at Yeouido St Marys Hospital and Seoul St Marys Hospital Both are located on Seoul Korea between May 2009 and June 2023
3 Selection criteria 31 Patients diagnosed with malignant lymphoma at Catholic Yeouido St Marys Hospital and Seoul St Marys Hospital between May 2009 and June 2023
32 Age 19 or older 33 Patients who treated with salvage chemotherapy for the relapsedrefractory lymphoma
4 Exclusion criteria 41 Patients suffering from acute leukemia 42 Patients additionally diagnosed with solid cancer colon cancer lung cancer stomach cancer etc during treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None